AstraZeneca structure adjustment!

Entering November, approaching the end of 2021, coupled with changes in the domestic pharmaceutical environment, in order to improve efficiency and respond to adjustments, many large foreign companies have made structural adjustments
.

AstraZeneca, which ranks first in the Chinese hospital market, is no exception.
On November 15th, AstraZeneca China officially announced to employees that some of the business structure has been adjusted, and the main changes are in the two core sectors: Jixian Business and Cardiovascular As for the metabolism and kidney business, the following two specific adjustments have been made:

Division of Hexian Business: Hexian Oncology Business was merged into Oncology Division, and non-oncology business was independent, becoming Jixian Chronic Disease Business Department
.

The Cardiovascular and Metabolism Division and the Renal Business Division were merged: the Cardiovascular, Renal and Metabolism Division was established
.

Based on the above adjustments, personnel appointments are as follows:

Zhang Haojiong, the current marketing director of the full-brand joint management of the Jixian Business Department, was appointed as the head (executive director) of the Jixian Oncology Business Department and directly reported to Yin Min, the general manager of the Oncology Business Department
.

Peng Jing, the current head of community business, was appointed as the head of the chronic disease business department (Assistant Vice President) of Jixian County, and Yu Yuping, the current head of the Cardiovascular and Metabolism Business Department, and the head of the Keding product line, took over as the head of the community business department.
Both of them report to Liu Qian, Vice President of AstraZeneca China
.

Zhu Tong, the current vice president of AstraZeneca China and head of the Cardiovascular and Metabolism Business Unit, was appointed as the head of the combined Cardiovascular, Kidney and Metabolism Business Unit, while Yang Shengbin, the head of the Kidney Business Unit, continues to be in charge of the kidney business team and reports directly Yu Zhutong
.

It is understood that AstraZeneca's long-term strategy of "expansion, innovation, and cooperation" remains unchanged, and the goal is still to maintain strong growth in China's business and stabilize the leading position of multinational pharmaceutical companies in the Chinese market
.

In addition, like other multinational pharmaceutical companies, another reason for the structural adjustment is that under the current medical policy, deepening the strategic cooperation and integration between the treatment fields and between the treatment fields and channels has become an inevitable consideration.